Search | Clinical Trials Finder

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 29
States / cities: Birmingham, Alabama • Palo Alto, California • Hartford, Connecticut + 26 more

Conditions: Venous Leg Ulcer
Interventions: S42909 100 mg, S42909 200 mg, S42909 400 mg, S42909 800 mg, S42909 1200 mg, Placebo Oral Tablet; Drug
Lead sponsor: Ilkos Therapeutic Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 14
States / cities: Carlsbad, California • Carmichael, California • Castro Valley, California + 10 more

Conditions: Acute Coronary Syndromes
Interventions: Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 4,614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 143
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more

Conditions: Influenza A
Interventions: VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 129
States / cities: Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 126 more

Conditions: Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea
Interventions: Crofelemer 125 MG [Mytesi], Placebo; Drug
Lead sponsor: Napo Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 27
States / cities: Prescott, Arizona • Anaheim, California • Corona, California + 24 more

Conditions: Type 2 Diabetes
Interventions: Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Chula Vista, California • Orlando, Florida

Conditions: Healthy Volunteers
Interventions: BMS-986177, Placebo (for BMS-986177), Clopidogrel, Aspirin; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Metastatic Colorectal Cancer
Interventions: Tivantinib, Placebo, Cetuximab, Irinotecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 24
States / cities: Beverly Hills, California • Encinitas, California • Fountain Valley, California + 21 more

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Tobacco Use Disorder
Interventions: memantine hydrochloride, placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Chronic Obstructive Pulmonary Disease, COPD
Interventions: QBW251, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Birmingham, Alabama • Fullerton, California • Waterbury, Connecticut + 11 more

Conditions: Congestive Heart Failure
Interventions: MCC-135, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 53
States / cities: Phoenix, Arizona • Tucson, Arizona • Carmichael, California + 47 more

Conditions: Down Syndrome
Interventions: Placebo, RO5186582; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Phoenix, Arizona • Decatur, Georgia • Chicago, Illinois + 5 more

Conditions: Hepatitis C, Chronic
Interventions: Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 85
States / cities: Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more

Conditions: Healthy Volunteers
Interventions: TAK-951, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Chronic Hepatitis C
Interventions: SOF, RBV, Placebo to match SOF, Placebo to match RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 50
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 40 more

Conditions: Obesity
Interventions: ARD-101, Placebo; Drug
Lead sponsor: Aardvark Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Treatment Resistant Depression
Interventions: Active study drug ( oral CBD), matching placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Liver Resection, Colorectal Carcinoma Liver Metastases
Interventions: HRX215 capsules, Placebo capsules; Drug
Lead sponsor: HepaRegeniX GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Rochester, Minnesota • Durham, North Carolina + 1 more

Conditions: Agitation, Dementia
Interventions: T2:C100, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 6 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Idelalisib, Bendamustine, Rituximab, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Fullerton, California • La Jolla, California • Santa Maria, California + 20 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BI 1015550, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 56
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 45 more

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 58
States / cities: Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more

Conditions: Alcohol Use Disorder, Bipolar Disorder, Schizoaffective Disorder Bipolar Type
Interventions: Placebo, Citicoline, Pregnenolone; Drug · Dietary Supplement
Lead sponsor: Sherwood Brown, MD, PhD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Miami, Florida • Dallas, Texas • Edinburg, Texas

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg; Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more

Search by objective public record fields.

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.

A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

A Study of TAK-951 in Healthy Adults

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

Study to Evaluate ARD-101 in Adults With Obesity

Cannabidiol for Treatment Resistant Depression

Safety of HRX215 in Patients After Minor and Major Liver Resection

Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures